Elopiprazole (; developmental code names DU-29840 and DU-29894) is an experimental antipsychotic drug of the phenylpiperazine family which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally. The drug acts as a dual dopamine D2 and D3 receptor antagonist and serotonin 5-HT1A receptor agonist (Ki = 0.45nM, 1.29nM, and 1.45nM, respectively). Conversely, it shows more than 50-fold lower affinity for the serotonin 5-HT2A and 5-HT2C receptors and various other targets. Elopiprazole was under development by Solvay Duphar. It reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development.
See also Phenylpiperazine List of investigational antipsychotics
References